Latest Healthcare News

dorsaVi reported a modest 1.9% rise in sales revenue to $330k in Q2 FY25, launched its AI-powered Video AI movement analysis platform, and initiated a blockchain integration partnership to enhance data security.

IMEXHS Limited reported a robust 34% increase in FY24 revenue to $26.5 million, driven by new contracts in Colombia and Peru that boosted its Annual Recurring Revenue to $30 million. Despite a slight EBITDA shortfall due to a bad debt expense, the company highlighted operational improvements and strengthened its regional footprint.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Credit Clear Limited has reported a robust first half of FY25 with record revenue and a significant rise in profitability, reaffirming its full-year guidance amid strong client acquisition.

ResMed Inc. has announced a quarterly ordinary dividend of USD 0.053 per share for holders of its ASX-listed Chess Depositary Instruments, with payments scheduled for March 2025.

Enlitic reported a robust 41.1% increase in quarterly revenue alongside the completion of its strategic acquisition of Laitek, positioning the company for operational cash flow break-even by the end of 2025.

Nido Education Limited has appointed Adam Lai, former PwC Sydney Managing Partner, as its new CEO starting February 2025, signaling a strategic push for significant expansion over the next five to eight years.

Lumos Diagnostics reported a robust Q2 FY25 with a 71% revenue increase to US$2.9 million, driven by strong product and service sales, alongside a strategic US$3 million BARDA partnership to advance its FebriDx test.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.